AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31377056 — intervention group
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl
Number of subjects: 2185
Study 31377056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2185
Study 28877893 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacteria-supplemented formula (107 CFU/g of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, B. longum subspecies infantis)
Number of subjects: 106
Study 28877893 — intervention group
Group type: COMPARATOR
Intervention: Control formula without bifidobacteria (placebo)
Number of subjects: 106
Study 28877893 — intervention group
Group type: COMPARATOR
Intervention: Breast milk (breastfed controls)
Number of subjects: 106
Study 28877893 — intervention group
Group type: COMPARATOR
Intervention: Infants birthed vaginally
Number of subjects: 106
Study 25052624 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Bereavement Program (FBP)
Number of subjects: 244
Study 25052624 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (books about bereavement)
Number of subjects: 244
Study 23239675 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 20
Study 23239675 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 21684151 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrubicin alone (A) 45mg/m² i.v. days 1-3
Number of subjects: 99
Study 21684151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin combined with amrubicin (PA) 60mg/m² i.v. day 1 and 40mg/m² i.v. days 1-3
Number of subjects: 99
Study 21684151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin combined with etoposide (PE) 75mg/m² i.v. day 1 and 100mg/m² days 2-3
Number of subjects: 99
Study 19809347 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) for 12 weeks
Number of subjects: 32
Study 19809347 — intervention group
Group type: COMPARATOR
Intervention: Placebo inspiratory muscle training (P-IMT) for 12 weeks
Number of subjects: 32
Study 16938697 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition of countries
Number of subjects: 0
Study 16938697 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-recall task
Number of subjects: 0
Study 16938697 — intervention group
Group type: EXPERIMENTAL
Intervention: Contiguity in free-recall output
Number of subjects: 0
Study 16938697 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses in a free-association task
Number of subjects: 0
Study 16938697 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction of recall from recognition
Number of subjects: 0
Study 16938697 — intervention group
Group type: EXPERIMENTAL
Intervention: News mentions of countries
Number of subjects: 0
Study 16938697 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative prosperity, population density, geographic area of countries
Number of subjects: 0
Study 15373937 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg aliskiren
Number of subjects: 15
Study 15373937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10949098 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation (imagery‐based relaxation tape)
Number of subjects: 50
Study 10949098 — intervention group
Group type: COMPARATOR
Intervention: Stress (Stroop test)
Number of subjects: 50
Study 10949098 — intervention group
Group type: COMPARATOR
Intervention: Control (video)
Number of subjects: 50
Study 9302482 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric strength training (strength)
Number of subjects: 22
Study 9302482 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric strength combined with flexibility training (strength and flexibility)
Number of subjects: 22
Study 9302482 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 8346829 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheridan design tube
Number of subjects: 48
Study 8346829 — intervention group
Group type: COMPARATOR
Intervention: Mallinckrodt design tube
Number of subjects: 48
Study 8346829 — intervention group
Group type: COMPARATOR
Intervention: Rusch design tube
Number of subjects: 48
Study 3538593 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG immunotherapy
Number of subjects: 161
Study 3538593 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin chemotherapy
Number of subjects: 161
Study 31735242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 85
Study 31735242 — intervention group
Group type: COMPARATOR
Intervention: Motivational Interviewing integrated with Cognitive-Behavioral Therapy (MI-CBT)
Number of subjects: 85
Study 28040753 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (no to 1 occlusion)
Number of subjects: 233
Study 28040753 — intervention group
Group type: EXPERIMENTAL
Intervention: Study population
Number of subjects: 233
Study 25886254 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg modified-release capsules for 12 months
Number of subjects: 226
Study 25886254 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules for 12 months
Number of subjects: 226
Study 25886254 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 226
Study 24210673 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIMAS
Number of subjects: 160
Study 24210673 — intervention group
Group type: COMPARATOR
Intervention: CG
Number of subjects: 160
Study 21521720 — intervention group
Group type: EXPERIMENTAL
Intervention: Highlighting relatedness
Number of subjects: 0
Study 21521720 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing about relatedness experiences
Number of subjects: 0
Study 21521720 — intervention group
Group type: EXPERIMENTAL
Intervention: Relatedness manipulation
Number of subjects: 0
Study 21521720 — intervention group
Group type: COMPARATOR
Intervention: Neutral task
Number of subjects: 0
Study 18520291 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel agents in lung cancer treatment
Number of subjects: 0
Study 16159704 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam (group 1)
Number of subjects: 93
Study 16159704 — intervention group
Group type: EXPERIMENTAL
Intervention: Periprostatic lidocaine injection (group 2)
Number of subjects: 93
Study 16159704 — intervention group
Group type: COMPARATOR
Intervention: No anesthetic (group 3)
Number of subjects: 93
Study 12653258 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC‐31260 30 mg
Number of subjects: 12
Study 12653258 — intervention group
Group type: COMPARATOR
Intervention: Furosemide 20 mg (F)
Number of subjects: 12
Study 12653258 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 20 mg plus OPC‐31260 30 mg (O+F)
Number of subjects: 12
Study 12653258 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC‐31260 30 mg (O)
Number of subjects: 12
Study 10755239 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg/week
Number of subjects: 782
Study 10755239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 782
Study 8874907 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 micrograms. kg‐1 morphine
Number of subjects: 120
Study 8874907 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 micrograms. kg‐1 buprenorphine
Number of subjects: 120
Study 8874907 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 micrograms. kg‐1 buprenorphine
Number of subjects: 120
Study 1576284 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (dosage regimens not specified)
Number of subjects: 50
Study 3888491 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 45
Study 3888491 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 45
Study 3888491 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 45
Study 31353413 — intervention group
Group type: EXPERIMENTAL
Intervention: Working Memory (WM) training
Number of subjects: 0
Study 31353413 — intervention group
Group type: COMPARATOR
Intervention: General knowledge training
Number of subjects: 0
Study 29730013 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-making preference scores
Number of subjects: 189
Study 29730013 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher decision-making preference scores
Number of subjects: 189
Study 29730013 — intervention group
Group type: EXPERIMENTAL
Intervention: Information-seeking preference scores
Number of subjects: 189
Study 29730013 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma control test scores, spirometry values, and health care use
Number of subjects: 189
Study 28851314 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A (4 weeks of oral S-1 and a 2-week rest over 12 months)
Number of subjects: 78
Study 26574829 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun jejunojejunostomy
Number of subjects: 30
Study 26574829 — intervention group
Group type: COMPARATOR
Intervention: Standard Whipple procedure
Number of subjects: 30
Study 23229932 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdilution OL-HDF
Number of subjects: 782
Study 23229932 — intervention group
Group type: COMPARATOR
Intervention: High-flux HD
Number of subjects: 782
Study 23229932 — intervention group
Group type: EXPERIMENTAL
Intervention: High-efficiency OL-HDF (subgroup with median substitution volume >17.4 L per session)
Number of subjects: 782
Study 23229932 — intervention group
Group type: EXPERIMENTAL
Intervention: High-efficiency OL-HDF
Number of subjects: 782
Study 21508750 — intervention group
Group type: EXPERIMENTAL
Intervention: Early insertion (1-3 days postpartum)
Number of subjects: 69
Study 21508750 — intervention group
Group type: COMPARATOR
Intervention: Standard insertion (4-8 weeks postpartum)
Number of subjects: 69
Study 21508750 — intervention group
Group type: EXPERIMENTAL
Intervention: Early insertion
Number of subjects: 69
Study 21508750 — intervention group
Group type: COMPARATOR
Intervention: Standard insertion
Number of subjects: 69
Study 18586462 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of Zn supplementation (as Zn sulfate)
Number of subjects: 44
Study 18586462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 16862245 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomepromazine (LMP)
Number of subjects: 38
Study 16862245 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (CPZ)
Number of subjects: 38
Study 16862245 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (HAL)
Number of subjects: 38
Study 15146420 — intervention group
Group type: COMPARATOR
Intervention: Diet plus exercise
Number of subjects: 316
Study 15146420 — intervention group
Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 316
Study 15146420 — intervention group
Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 316
Study 15146420 — intervention group
Group type: COMPARATOR
Intervention: Weight-loss groups (diet and diet plus exercise)
Number of subjects: 316
Study 15146420 — intervention group
Group type: COMPARATOR
Intervention: Joint space width
Number of subjects: 316
Study 11235596 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical imaging method with acetic acid application
Number of subjects: 0
Study 11235596 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical imaging method
Number of subjects: 0
Study 9451749 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing pain education program for surgical cancer nurses
Number of subjects: 0
Study 9451749 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8166893 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine/bupivacaine
Number of subjects: 38
Study 8166893 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 38
Study 8166893 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine
Number of subjects: 38
Study 8166893 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine
Number of subjects: 38
Study 3137764 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam/alfentanil
Number of subjects: 0
Study 3137764 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone/alfentanil/nitrous oxide
Number of subjects: 0
Study 31022103 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand width at 120% of biacromial width
Number of subjects: 10
Study 31022103 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand width at 170% of biacromial width
Number of subjects: 10
Study 30328056 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined smoking cessation and pain management intervention
Number of subjects: 30
Study 30328056 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 30
Study 27655646 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg thiamylal
Number of subjects: 48
Study 27655646 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mg/kg propofol
Number of subjects: 48
Study 24656609 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg or 300 mg subcutaneous daclizumab HYP every 4 weeks for 52 weeks (treatment initiation group)
Number of subjects: 517
Study 24656609 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment with daclizumab HYP (no washout)
Number of subjects: 517
Study 24656609 — intervention group
Group type: EXPERIMENTAL
Intervention: Washout and re-initiation group (300 mg daclizumab HYP)
Number of subjects: 517
Study 24656609 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous treatment group
Number of subjects: 517
Study 24656609 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment initiation group
Number of subjects: 517
Study 24656609 — intervention group
Group type: EXPERIMENTAL
Intervention: Washout and re-initiation group
Number of subjects: 517
Study 21525406 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) with cisplatin 75 mg/m(2), epirubicin 75 mg/m(2) and paclitaxel (Taxol) 175 mg/m(2) (CEP) followed by concomitant radiotherapy (RT) and weekly cisplatin 40 mg/m(2)
Number of subjects: 141
Study 21525406 — intervention group
Group type: COMPARATOR
Intervention: Concomitant chemoradiotherapy (CCRT) alone
Number of subjects: 141
Study 21029664 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery combined with chemotherapy (4-6 cycles of etoposide + cisplatin or carboplatin)
Number of subjects: 37
Study 21029664 — intervention group
Group type: COMPARATOR
Intervention: Non-surgery chemotherapy (6 cycles of etoposide + cisplatin or carboplatin)
Number of subjects: 37
Study 18221449 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation (R)
Number of subjects: 49
Study 18221449 — intervention group
Group type: EXPERIMENTAL
Intervention: Quiet Sitting (QS)
Number of subjects: 49
Study 18221449 — intervention group
Group type: COMPARATOR
Intervention: GAD patients
Number of subjects: 49
Study 15925449 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored follow-up sessions
Number of subjects: 0
Study 15925449 — intervention group
Group type: COMPARATOR
Intervention: Group follow-up sessions
Number of subjects: 0
Study 14693901 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Hockey video
Number of subjects: 0
Study 14693901 — intervention group
Group type: COMPARATOR
Intervention: Control teams
Number of subjects: 0
Study 10969262 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with rickets
Number of subjects: 123
Study 10969262 — intervention group
Group type: COMPARATOR
Intervention: Control children
Number of subjects: 123
Study 8791030 — intervention group
Group type: EXPERIMENTAL
Intervention: 311C90 20 mg
Number of subjects: 40
Study 8791030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1732975 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging of the TMJ
Number of subjects: 32
Study 1732975 — intervention group
Group type: COMPARATOR
Intervention: Clinical examination
Number of subjects: 32
Study 1732975 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 32
Study 6428555 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation with a clinical psychologist in addition to usual primary care management
Number of subjects: 2
Study 6428555 — intervention group
Group type: COMPARATOR
Intervention: Usual primary care management
Number of subjects: 2
Study 31504535 — intervention group
Group type: EXPERIMENTAL
Intervention: Transatrial approach
Number of subjects: 0
Study 31504535 — intervention group
Group type: COMPARATOR
Intervention: Transventricular approach
Number of subjects: 0
Study 29971581 — intervention group
Group type: EXPERIMENTAL
Intervention: With-drain
Number of subjects: 66
Study 29971581 — intervention group
Group type: COMPARATOR
Intervention: No-drain
Number of subjects: 66
Study 26908330 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 471
Study 26908330 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 471
Study 25123656 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) alone
Number of subjects: 1129
Study 22519849 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil during recovery from propofol anaesthesia
Number of subjects: 74
Study 22519849 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil during recovery from sevoflurane anaesthesia
Number of subjects: 74
Study 21235068 — intervention group
Group type: EXPERIMENTAL
Intervention: EA + cupping
Number of subjects: 128
Study 21235068 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 128
Study 18203907 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified complementary food (FCF), Mi Papilla, consumed over 11 months.
Number of subjects: 0
Study 18203907 — intervention group
Group type: COMPARATOR
Intervention: Control group (same-age children in nearby communities eligible for the program 1 year later).
Number of subjects: 0
Study 18203907 — intervention group
Group type: EXPERIMENTAL
Intervention: PANN 2000 children (older subgroup 12-14 months at program start).
Number of subjects: 0
Study 15976152 — intervention group
Group type: EXPERIMENTAL
Intervention: Child adherence to weighing and preplanning for celebrations where high-fat foods are served; Parent adherence to praising the child and modeling healthy eating habits
Number of subjects: 110
Study 15976152 — intervention group
Group type: EXPERIMENTAL
Intervention: Child adherence to recording food and calories; Parent adherence to modeling healthy eating habits
Number of subjects: 110
Study 15976152 — intervention group
Group type: EXPERIMENTAL
Intervention: Child weighing and preplanning; Parent modeling
Number of subjects: 110
Study 15976152 — intervention group
Group type: EXPERIMENTAL
Intervention: Child recording and parent modeling
Number of subjects: 110
Study 12888371 — intervention group
Group type: EXPERIMENTAL
Intervention: Active study population (ASP)
Number of subjects: 141
Study 12888371 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-shifting from invasive stage II or worse to invasive stage I
Number of subjects: 141
Study 12888371 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-shifting from invasive stage I to DCIS
Number of subjects: 141
Study 12888371 — intervention group
Group type: EXPERIMENTAL
Intervention: Assumed stage-shifting from invasive disease to DCIS
Number of subjects: 141
Study 12888371 — intervention group
Group type: COMPARATOR
Intervention: Randomised trials of breast cancer screening
Number of subjects: 141
Study 18425651 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed message
Number of subjects: 76
Study 18425651 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed message
Number of subjects: 76
Study 18425651 — intervention group
Group type: COMPARATOR
Intervention: Neutrally-framed message
Number of subjects: 76
Study 8780614 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography
Number of subjects: 9477
Study 8780614 — intervention group
Group type: COMPARATOR
Intervention: No Mammography
Number of subjects: 9477
Study 1812497 — intervention group
Group type: EXPERIMENTAL
Intervention: Levoprotiline
Number of subjects: 9
Study 1812497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1812497 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 9
Study 3888463 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol treatment (10 mg twice daily)
Number of subjects: 0
Study 3888463 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol treatment
Number of subjects: 0
Study 29936188 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk prediction score including early treatment response
Number of subjects: 304
Study 29936188 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk prediction score
Number of subjects: 304
Study 29936188 — intervention group
Group type: EXPERIMENTAL
Intervention: External validation of risk prediction score
Number of subjects: 304
Study 29156488 — intervention group
Group type: EXPERIMENTAL
Intervention: cobimetinib plus vemurafenib
Number of subjects: 210
Study 29156488 — intervention group
Group type: COMPARATOR
Intervention: vemurafenib
Number of subjects: 210
Study 26454105 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular morning hydrocortisone intake
Number of subjects: 31
Study 26454105 — intervention group
Group type: EXPERIMENTAL
Intervention: Postponement of morning hydrocortisone intake
Number of subjects: 31
Study 26454105 — intervention group
Group type: COMPARATOR
Intervention: Healthy matched controls
Number of subjects: 31
Study 25096769 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol infusion (0.5 mg/kg/min)
Number of subjects: 45
Study 25096769 — intervention group
Group type: COMPARATOR
Intervention: Esmolol bolus (1.5 mg/kg IV)
Number of subjects: 45
Study 25096769 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% NaCl)
Number of subjects: 45
Study 22056980 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-free beverages (10% sugar equivalent in taste and appearance)
Number of subjects: 642
Study 22056980 — intervention group
Group type: COMPARATOR
Intervention: Sugar-sweetened beverages
Number of subjects: 642
Study 19168247 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES), n=37
Number of subjects: 75
Study 19168247 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS), n=38
Number of subjects: 75
Study 19168247 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SES and BMS
Number of subjects: 75
Study 22101221 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin administered by convection-enhanced delivery (CED)
Number of subjects: 18
Study 16306032 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine 400 mg once daily
Number of subjects: 578